Pfizer makes haste to go EZ
The company sticks with EZH2, despite others adding EZH1 inhibition.
FDA green and red lights: July 2024
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
The company sticks with EZH2, despite others adding EZH1 inhibition.
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
